ROCKET PHARMACEUTICALS INC (RCKT) Stock Price & Overview

NASDAQ:RCKT • US77313F1066

Current stock price

3.55 USD
-0.07 (-1.93%)
At close:
3.56 USD
+0.01 (+0.28%)
After Hours:

The current stock price of RCKT is 3.55 USD. Today RCKT is down by -1.93%. In the past month the price decreased by -23.49%. In the past year, price decreased by -30.66%.

RCKT Key Statistics

52-Week Range2.19 - 8.26
Current RCKT stock price positioned within its 52-week range.
1-Month Range3.38 - 5.45
Current RCKT stock price positioned within its 1-month range.
Market Cap
385.424M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.98
Dividend Yield
N/A

RCKT Stock Performance

Today
-1.93%
1 Week
-24.31%
1 Month
-23.49%
3 Months
+2.60%
Longer-term
6 Months +12.70%
1 Year -30.66%
2 Years -83.50%
3 Years -80.19%
5 Years -92.26%
10 Years N/A

RCKT Stock Chart

ROCKET PHARMACEUTICALS INC / RCKT Daily stock chart

RCKT Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to RCKT. When comparing the yearly performance of all stocks, RCKT is a bad performer in the overall market: 82.47% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

RCKT Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to RCKT. The financial health of RCKT is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RCKT Earnings

Next Earnings DateMay 6, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.38
Revenue Reported
EPS Surprise 17.82%
Revenue Surprise %

RCKT Forecast & Estimates

20 analysts have analysed RCKT and the average price target is 8.37 USD. This implies a price increase of 135.73% is expected in the next year compared to the current price of 3.55.


Analysts
Analysts73
Price Target8.37 (135.77%)
EPS Next Y21.6%
Revenue Next YearN/A

RCKT Groups

Sector & Classification

RCKT Financial Highlights

Over the last trailing twelve months RCKT reported a non-GAAP Earnings per Share(EPS) of -1.98. The EPS increased by 27.47% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-223.12M
Industry RankSector Rank
PM (TTM) N/A
ROA -67.52%
ROE -80.49%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%38.71%
Sales Q2Q%N/A
EPS 1Y (TTM)27.47%
Revenue 1Y (TTM)N/A

RCKT Ownership

Ownership
Inst Owners85.93%
Shares108.57M
Float103.53M
Ins Owners4.15%
Short Float %14.19%
Short Ratio4.15

About RCKT

Company Profile

RCKT logo image Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 202 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

Company Info

IPO: 2015-02-18

ROCKET PHARMACEUTICALS INC

9 Cedarbrook Drive

Cranbury NEW JERSEY 08512 US

CEO: Gaurav Shah

Employees: 202

RCKT Company Website

RCKT Investor Relations

Phone: 16464409100

ROCKET PHARMACEUTICALS INC / RCKT FAQ

What does RCKT do?

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 202 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.


Can you provide the latest stock price for ROCKET PHARMACEUTICALS INC?

The current stock price of RCKT is 3.55 USD. The price decreased by -1.93% in the last trading session.


What is the dividend status of ROCKET PHARMACEUTICALS INC?

RCKT does not pay a dividend.


What is the ChartMill rating of ROCKET PHARMACEUTICALS INC stock?

RCKT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What sector and industry does ROCKET PHARMACEUTICALS INC belong to?

ROCKET PHARMACEUTICALS INC (RCKT) operates in the Health Care sector and the Biotechnology industry.


What is the employee count for RCKT stock?

ROCKET PHARMACEUTICALS INC (RCKT) currently has 202 employees.


Who owns ROCKET PHARMACEUTICALS INC?

You can find the ownership structure of ROCKET PHARMACEUTICALS INC (RCKT) on the Ownership tab.